Phase II studies with Refametinib or Refametinib plus Sorafenib in patients with RAS-mutated Hepatocellular Carcinoma by Lim, Ho Yeong et al.
 
 
Phase II studies with Refametinib or Refametinib
plus Sorafenib in patients with RAS-mutated
Hepatocellular Carcinoma
Lim, Ho Yeong; Merle, Philippe; Weiss, Karl-Heinz; Yau, Thomas CC; Ross, Paul;
Mazzaferro, Vincenzo; Blanc, Jean-Frédéric; Ma, Yuk; Yen, Chia-Jui; Kocsis, Judit; Choo, Su
Pin; Sukeepaisarnjaroen, Wattana; Gérolami,  René; Dufour, Jean-François; Gane, Edward J;
Ryoo, Baek-Yeol; Peck-Radosavljevic, Markus; Dao,  Thong; Yeo, Winnie; Lamlertthon,
Wisut
DOI:
10.1158/1078-0432.CCR-17-3588
Document Version
Peer reviewed version
Citation for published version (Harvard):
Lim, HY, Merle, P, Weiss, K-H, Yau, TCC, Ross, P, Mazzaferro, V, Blanc, J-F, Ma, Y, Yen, C-J, Kocsis, J, Choo,
SP, Sukeepaisarnjaroen, W, Gérolami, R, Dufour, J-F, Gane, EJ, Ryoo, B-Y, Peck-Radosavljevic, M, Dao, T,
Yeo, W, Lamlertthon, W, Thongsawat, S, Teufel, M, Roth, K, Reis, D, Childs, BH, Krissel, H & Llovet, JM 2018,
'Phase II studies with Refametinib or Refametinib plus Sorafenib in patients with RAS-mutated Hepatocellular
Carcinoma' Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-3588
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 06/08/2018
This is the accepted manuscript for a forthcoming publication in Clinical Cancer Research.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 13. Aug. 2019
1 
Phase II Studies with Refametinib or Refametinib plus Sorafenib in 1 
Patients with RAS-mutated Hepatocellular Carcinoma 2 
Running title: Refametinib or Refametinib + Sorafenib in RAS-mutated HCC 3 
Ho Yeong Lim
1,*
, Philippe Merle
2
, Karl Heinz Weiss
3
, Thomas Yau
4
, Paul Ross
5
, Vincenzo 4 
Mazzaferro
6
, Jean-Frédéric Blanc
7
, Yuk Ting Ma
8
, Chia Jui Yen
9
, Judit Kocsis
10
, Su Pin 5 
Choo
11
, Wattana Sukeepaisarnjaroen
12
, René Gérolami
13
, Jean-François Dufour
14
, Edward J. 6 
Gane
15
, Baek-Yeol Ryoo
16
, Markus Peck-Radosavljevic
17,†
, Thong Dao
18
, Winnie Yeo
19
, 7 
Wisut Lamlertthon
20
, Satawat Thongsawat
21
, Michael Teufel
22
, Katrin Roth
23
, Diego Reis
24
, 8 
Barrett H. Childs
22
, Heiko Krissel
23
, and Josep M. Llovet
25,26,27*
 9 
1
Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, 10 
Seoul, Korea; 
2
Service of Hepato-Gastroenterology, Hepatology Unit, Croix-Rousse 11 
Hospital, Lyon, France; 
3
Section of Transplant Hepatology, Liver Cancer Center Heidelberg, 12 
Heidelberg, Germany; 
4
Department of Medicine, Queen Mary Hospital, Hong Kong; 13 
5
Cancer Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, UK; 6Gastrointestinal 14 
Surgery and Liver Transplant Unit, The Fondazione IRCCS Istituto Nazionale Tumori 15 
(National Cancer Institute) and University of Milan, Milan, Italy; 
7
Service of Hepato-16 
Gastroenterology and Digestive Oncology, Hôpital Haut-Lévêque, Bordeaux, France; 17 
8
Department of Medical Oncology, University Hospitals Birmingham NHS Foundation Trust, 18 
Birmingham, UK; 
9
Division of Hematology and Oncology, National Cheng Kung University 19 
Hospital, Tainan, Taiwan; 
10
Oncology Department, Debrecen University Clinical Center, 20 
Debrecen, Hungary; 
11
Division of Medical Oncology, National Cancer Centre Singapore, 21 
Singapore; 
12
Department of Medicine, Srinagarind Hospital, Khon Kaen, Thailand; 
13
Service 22 
of Hepato-Gastroenterology, Aix-Marseille University, Marseille, France; 
14
Department of 23 
Hepatology, University Clinic for Visceral Surgery and Medicine, University Hospital of 24 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 
2 
Bern, Bern, Switzerland; 
15
New Zealand Liver & Transplant Unit, Auckland City Hospital, 25 
Auckland, New Zealand; 
16
Department of Oncology, Asan Medical Center, Seoul, Korea; 26 
17
Department of Gastroenterology and Hepatology, Endocrinology, Rheumatology and 27 
Nephrology, Medical University of Vienna, Vienna, Austria; 
18
Service of Hepato-28 
Gastroenterology and Nutrition, Caen University Hospital, Caen, France; 
19
Department of 29 
Clinical Oncology, Chinese University of Hong Kong, Hong Kong; 
20
Chulabhorn Hospital, 30 
Bangkok, Thailand; 
21
Department of Internal Medicine, Maharaj Nakorn Chiang Mai 31 
Hospital, Chiang Mai, Thailand; 
22
Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, 32 
USA; 
23
Bayer AG, Berlin, Germany; 
24
Medical and Data Management, Bayer S.A., São 33 
Paulo, Brazil; 
25
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New 34 
York, NY, USA; 
26
Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver 35 
Cancer Group (BCLC), IDIBAPS-Hospital Clínic de Barcelona, University of Barcelona, 36 
Barcelona, Spain; 
27
Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain 37 
†
Current affiliation: Department of Gastroenterology/Hepatology, Endocrinology and 38 
Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria 39 
Financial Support 40 
These studies were supported by Bayer AG.  The study sponsor played a role in the design of 41 
the study, data interpretation, writing of the manuscript, and the decision to submit for 42 
publication.  At each study center, the principal investigator was responsible for the study.  43 
Medical writing support for the manuscript was funded by the study sponsor, based on 44 
detailed direction and feedback from all authors.  Medical writing assistance was provided by 45 
Laura Badtke, PhD, at Complete HealthVizion, Chicago, IL, USA, based on detailed 46 
discussion and feedback from all authors.  Medical writing assistance was funded by 47 
Bayer AG. 48 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 
3 
*Corresponding Authors: 49 
Ho Yeong Lim, Division of Hematology-Oncology, Department of Medicine, Samsung 50 
Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea. Phone: 82-2-51 
3410-0914; Fax: 82-2-3410-1754; E-mail: hoylim@skku.edu 52 
Josep M. Llovet, Director, Mount Sinai Liver Cancer Program, Division of Liver Diseases, 53 
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., 11F-54 
70, Box 1123, New York, NY 10029, USA. Phone: 212-659-9503; Fax: 212-849-2574; E-55 
mail: josep.llovet@mssm.edu; Assistant: Melody Tam (melody.tam@mssm.edu) 56 
Disclosure of Potential Conflicts of Interest 57 
K.H. Weiss reports grants from Novartis and MSD, personal fees from Bayer, GMPO, and 58 
Vivet Therapeutics, and grants and personal fees from Bristol-Myers Squibb, Univar, Wilson 59 
Therapeutics, and Alexion.  P. Ross reports grants from Sanofi Aventis, fees for educational 60 
sessions from BMS, travel support from BMS, Sirtex, Bayer, Merck Serono, Servier, Amgen, 61 
and Celgene, advisory board fees from BMS, Sirtex, Bayer, Merck Serono, Servier, and 62 
Celgene, and speaking fees from Merck Serono, Sirtex, and Bayer.  V. Mazzaferro reports 63 
personal fees from Bayer and BTG.  J.-F. Blanc reports personal fees from Bayer SP, Lilly, 64 
and BMS. Y.T. Ma reports honoraria and travel support from Bayer and consultancy fees 65 
from Baxalta UK, Ltd.  S.P. Choo reports grants from Bristol-Myers Squibb, travel support 66 
from Amgen, and honoraria from Bristol-Myers Squibb, Bayer, Novartis, and Sirtex.  J.-F. 67 
Dufour reports participating in advisory committees for AbbVie, Bayer, Bristol-Myers 68 
Squibb, Falk, Genfit, Gilead Sciences, Intercept, Lilly, Merck, and Novartis, speaking and 69 
teaching for AbbVie, Bayer, Bristol-Myers Squibb, Genfit, Gilead Science, and Novartis, and 70 
an unrestricted research grant from Bayer.  E.J. Gane reports participating in clinical advisory 71 
committees or speaker bureaus for Alios, AbbVie, Arrowhead, Janssen, Merck, Gilead 72 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 
4 
Sciences, and Mylan.  M. Peck-Radosavljevic reports being an investigator for AbbVie, 73 
ArQule-Daiichi, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Imclone, Lilly, MSD, 74 
Novartis, and Roche, grant support from AbbVie, ArQule-Daiichi, Bayer, MSD, and Roche, 75 
and acting as a speaker or advisor for Abbott, Bayer, Bristol-Myers Squibb, Boehringer 76 
Ingelheim, Lilly, MSD, and Roche.  T. Dao reports congress and travel support from Bayer, 77 
Gilead Sciences, AbbVie, and MSD, and being an investigator for Lilly.  M. Teufel and B.H. 78 
Childs are employees of Bayer HealthCare Pharmaceuticals, Inc.  K. Roth and H. Krissel are 79 
employees of Bayer AG.  H. Krissel also reports patent BHC 133035 EP 01 pending.  D. Reis 80 
is an employee of and has received personal fees from Bayer S.A.  J.M. Llovet reports 81 
research/education grants from Bayer, Blueprint Medicines, Boehringer Ingelheim, and 82 
Incyte and consulting fees from Eli Lilly, Bayer, BMS, Blueprint Medicines, Eisai, Celsion, 83 
and Boehringer Ingelheim.  The remaining authors declare no potential conflicts of interest. 84 
Authors’ Contributions 85 
All authors contributed to the collection and analysis of the data and to the writing of the 86 
manuscript, and approved the final version before submission.  H.Y. Lim and J.M. Llovet: 87 
study design; coordinating investigators for the review; approved the clinical study reports; 88 
had full access to all the data in the studies; vouch for the integrity of the data analyses; had 89 
final responsibility for the decision to submit.  K. Roth: statistical analysis.  M. Teufel: study 90 
design, interpretation of the biomarker results.  D. Reis, B.H. Childs, and H. Krissel: study 91 
design. 92 
ClinicalTrials.gov numbers: NCT01915589, NCT01915602 93 
Keywords: Hepatocellular carcinoma, KRAS, refametinib, sorafenib, BEAMing 94 
Word count: 4717 (max 5000) 95 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 
5 
Number of figures and tables: 3 figures and 3 tables  96 
Research. 
on August 6, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 27, 2018; DOI: 10.1158/1078-0432.CCR-17-3588 
6 
Translational Relevance 97 
The frequency of RAS mutations in hepatocellular carcinoma (HCC) is reported to be ~4%.  98 
In this study, we report on the use of a liquid biopsy to prospectively screen patients with 99 
HCC for RAS mutations using circulating tumor DNA for treatment with the MEK inhibitor 100 
refametinib in monotherapy or in combination with sorafenib.  The low prevalence of RAS 101 
mutations in HCC was confirmed (4.4% of patients).  RAS mutational status was confirmed 102 
by next-generation sequencing using circulating tumor DNA, which allowed for the 103 
determination of the mutational landscape in patients with HCC.  The most frequently 104 
detected mutations were in TERT, TP53, and β-catenin, confirming data reported in The 105 
Cancer Genome Atlas.  This is the first study using a liquid biopsy for large-scale mutational 106 
testing, which offers the opportunity for comprehensive mutational analysis using a 107 
non-invasive approach.  108 
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Abstract 109 
Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in 110 
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC).  111 
Two phase II studies evaluated the efficacy of refametinib monotherapy and refametinib plus 112 
sorafenib in patients with RAS-mutant unresectable or metastatic HCC. 113 
Methods: Eligible patients with RAS mutations of cell-free circulating tumor DNA (ctDNA) 114 
determined by beads, emulsion, amplification, and magnetics technology received twice-daily 115 
refametinib 50 mg ± sorafenib 400 mg.  Potential biomarkers were assessed in ctDNA via 116 
next-generation sequencing (NGS). 117 
Results: Of 1318 patients screened, 59 (4.4%) had a RAS mutation, of whom 16 received 118 
refametinib and 16 received refametinib plus sorafenib.  With refametinib monotherapy, the 119 
objective response rate (ORR) was 0%, the disease control rate (DCR) was 56.3%, overall 120 
survival (OS) was 5.8 months, and progression-free survival (PFS) was 1.9 months.  With 121 
refametinib plus sorafenib, the ORR was 6.3%, the DCR was 43.8%, OS was 12.7 months, 122 
and PFS was 1.5 months.  In both studies, time to progression was 2.8 months.  Treatment-123 
emergent toxicities included fatigue, hypertension, and acneiform rash.  Twenty-seven 124 
patients had ctDNA samples available for NGS.  The most frequently detected mutations 125 
were in TERT (63.0%), TP53 (48.1%), and β-catenin (CTNNB1; 37.0%). 126 
Conclusions: Prospective testing for RAS family mutations using ctDNA was a feasible, non-127 
invasive approach for large-scale mutational testing in HCC patients.  A median OS of 128 
12.7 months with refametinib plus sorafenib in this small population of RAS-mutant patients 129 
may indicate a synergistic effect between sorafenib and refametinib – this preliminary finding 130 
should be further explored. 131 
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Introduction 133 
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide (1,2), 134 
and the prognosis for HCC remains extremely poor (2,3).  The recommended standard of care 135 
in advanced HCC is treatment with the multikinase inhibitor sorafenib (3-5).  Lenvatinib has 136 
been shown to be non-inferior to sorafenib in a recent phase III trial (6).  In second-line, the 137 
multikinase inhibitor regorafenib has been approved after showing significantly improved 138 
survival versus placebo in patients who had disease progression on sorafenib (7).  The kinase 139 
inhibitor cabozantinib has also demonstrated promising survival improvements versus 140 
placebo as second-line therapy in a phase III trial (8).  Immunotherapy has shown promise in 141 
HCC, with the immune checkpoint inhibitor nivolumab recently approved for the second-line 142 
treatment of advanced HCC based on durable responses observed in a phase I/II trial (9).  143 
Treatment with the monoclonal antibody ramucirumab has shown survival improvement 144 
versus placebo in patients progressing to sorafenib with alpha-fetoprotein >400 ng/ml (10).   145 
Poor prognosis and a lack of treatment options highlight a need for additional viable 146 
treatment regimens in the advanced setting. 147 
Refametinib (BAY 86-9766; Bayer AG, Berlin, Germany) is an oral, potent, non-adenosine 148 
triphosphate competitive inhibitor targeting MEK 1 and 2 (11), which play a central role in 149 
the RAS signal transduction cascade.  RAS-MAPK signaling has been implicated in tumor 150 
progression and dissemination in HCC (2).  A phase I study of the combination of 151 
refametinib with sorafenib in patients with advanced malignancies including HCC 152 
demonstrated a favorable safety profile and pharmacokinetic profile at a maximum tolerated 153 
dose of refametinib 50 mg twice daily in combination with sorafenib 400 mg twice daily (12). 154 
The analysis of cell-free circulating tumor DNA (ctDNA) using beads, emulsion, 155 
amplification, and magnetics technology (BEAMing; Sysmex Inostics GmbH, Hamburg, 156 
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Germany) enables tumor genotyping at the time of treatment and offers a viable, non-invasive 157 
approach to identifying clinically relevant mutations (13,14).  BEAMing may therefore be a 158 
feasible tool to support the need for the identification of predictive biomarkers in HCC (3), 159 
through proof-of-concept studies.  Previous proof-of-concept studies of kinase inhibitors in 160 
other cancer types have successfully detected predictive mutations, such as vemurafenib in 161 
patients with inoperable melanoma with a BRAF
V600
 mutation (15) and crizotinib in patients 162 
with non-small-cell lung cancer with EML4-ALK fusion (16). 163 
A retrospective analysis in a phase II study evaluating refametinib plus sorafenib in Asian 164 
patients with HCC found that patients with RAS mutations exhibited a robust clinical 165 
response compared with patients with wild-type RAS (objective tumor response rate [ORR]: 166 
3/4 patients [75.0%] compared with 1/65 patients [1.5%], respectively) (17).  Here we 167 
describe the first proof-of-concept studies based on mutations conducted in patients with 168 
HCC.  Two phase II studies prospectively evaluated the efficacy of refametinib monotherapy 169 
(NCT01915589) and refametinib plus sorafenib (NCT01915602) in patients with 170 
unresectable or metastatic HCC with mutated RAS, as determined by BEAMing of ctDNA. 171 
Patients and Methods 172 
Study design 173 
These were two phase II, prospective, single-arm, multicenter, uncontrolled, open-label 174 
studies.  The primary objective was to evaluate the efficacy of refametinib alone or in 175 
combination with sorafenib in patients with RAS- (KRAS- or NRAS-) mutated unresectable or 176 
metastatic HCC.  The primary efficacy variable was the central radiologic assessment of 177 
ORR (complete response [CR] plus partial response [PR]) according to modified Response 178 
Evaluation Criteria in Solid Tumors (mRECIST) (18).  The secondary objective was safety, 179 
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and additional objectives included evaluation of biomarkers aiming to identify biomarkers or 180 
biomarker signatures which could correspond to therapy response.  Secondary efficacy 181 
variables included centrally assessed ORR according to RECIST version 1.1, investigator-182 
assessed ORR according to mRECIST and RECIST version 1.1, overall survival, disease 183 
control rate, time to radiographic tumor progression, duration of response, and progression-184 
free survival. 185 
Fifteen patients with RAS mutations were planned to be included in the first stage of each 186 
study.  The second stage was to be initiated if five or more of these patients had a confirmed 187 
objective response according to mRECIST. 188 
Important protocol amendments 189 
In the refametinib monotherapy study, the protocol was amended once, with changes 190 
implemented globally.  Prior cytotoxic chemotherapy was added as an exclusion criterion to 191 
omit a population of overtreated patients who may have been different from patients 192 
conventionally treated with sorafenib; this change affected eligibility criteria for RAS 193 
mutation testing and treatment exclusion criteria.  An exclusion criterion was also added 194 
regarding women of childbearing potential to reduce the time gap between the pregnancy 195 
evaluation and the beginning of treatment. 196 
In the refametinib plus sorafenib study, the protocol was amended twice.  Changes were 197 
implemented globally and included the following amendments: patients with a corrected QT 198 
interval >480 ms at the time of screening were excluded from the study because of the 199 
potential for QT prolongation with sorafenib; the exclusion criterion regarding women of 200 
childbearing potential was amended to reduce the time gap between the pregnancy evaluation 201 
and the beginning of treatment; the exclusion criterion regarding systemic anticancer therapy 202 
was clarified, as patients with prior systemic anticancer therapy were not eligible for this 203 
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study.  In addition, a dose-modification scheme for hepatotoxic events was included, because 204 
hepatotoxicity is an “identified risk” for the refametinib–sorafenib combination. 205 
Amendments to the statistical analysis plan for the refametinib plus sorafenib study included 206 
the collection of survival data to be continued until the last patient’s last visit instead of until 207 
12 weeks after the last patient’s first treatment, or earlier if all patients had withdrawn from 208 
the study.  A data rule was also added regarding tumor assessment by centralized blinded 209 
reading; for cases with missing adjudication for patients who had completed or withdrawn 210 
from treatment at the time of primary analysis, the worst-case approach was to be applied. 211 
Patients 212 
Written, informed consent was obtained from all patients.  The study protocol conforms to 213 
the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by 214 
the institutions’ human research committees. 215 
Eligibility criteria for RAS mutational testing included: age ≥18 years with unresectable or 216 
metastatic HCC, confirmed histologically (mandatory for non-cirrhotic patients) or by non-217 
invasive radiologic criteria; Eastern Cooperative Oncology Group performance status of 0 or 218 
1; and life expectancy ≥12 weeks.  Prior use of targeted agents, experimental therapy, or 219 
systemic anticancer treatment was not allowed, although prior sorafenib treatment was 220 
permitted in patients who received refametinib only. 221 
Treatment eligibility criteria included: KRAS or NRAS mutation based on BEAMing plasma 222 
test; Child-Pugh class A liver function status; at least one uni-dimensional measurable lesion 223 
by computed tomography or magnetic resonance imaging; and Eastern Cooperative Oncology 224 
Group performance status of 0 or 1.  Treatment exclusion criteria included: any cancer 225 
curatively treated less than 3 years before study entry (except cervical carcinoma in situ, 226 
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treated basal cell carcinoma, and superficial bladder tumors); eligibility for surgery, liver 227 
transplantation, ablation, or transarterial chemoembolization for hepatocellular carcinoma; 228 
renal failure requiring hemo- or peritoneal dialysis; a history of cardiac disease; or 229 
uncontrolled hypertension. 230 
Treatment 231 
In both studies, eligible patients harboring RAS mutations received refametinib 50 mg twice 232 
daily in 21-day cycles.  In the refametinib plus sorafenib study, patients also received 233 
standard sorafenib (400 mg twice daily), starting with a dose of 600 mg daily (200 mg in the 234 
morning plus 400 mg in the evening) in cycle 1, escalating to the standard sorafenib dose in 235 
cycle 2 if no hand-foot skin reaction, fatigue, or gastrointestinal toxicities of grade ≥2 236 
occurred.  Patients received treatment on a continuous basis until radiologic disease 237 
progression, clinical progression, or other criteria for discontinuation of treatment were met. 238 
Assessments 239 
ctDNA from plasma samples collected in the pre-treatment period was centrally evaluated for 240 
RAS mutational status using BEAMing technology (13), with a limit of detection at 0.02% 241 
mutant allele.  Tumor assessments were performed at screening and every 6 weeks.  242 
Treatment response was centrally assessed according to mRECIST for the primary endpoint, 243 
and was also investigator-assessed according to mRECIST (18).  Safety, including adverse 244 
events (AEs) and concomitant medications, was monitored throughout the studies.  Creatine 245 
phosphokinase (CPK) increase of grade ≥3 was considered an AE of special interest and was 246 
to be reported as a serious AE (SAE).  Plasma samples for biomarker analysis were collected 247 
at screening, at cycle 1, days 1 and 15, and at cycle 2, day 15.  Peripheral whole-blood 248 
samples from patients with mutated RAS were analyzed for detection of genomic alterations 249 
using FoundationACT
®
 (Foundation Medicine
®
, Cambridge, MA, USA), a targeted next-250 
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generation sequencing (NGS)-based ctDNA assay (19).  The detection limit of 251 
FoundationACT
®
 is specified at 0.1% mutant allele frequency, i.e. a lower sensitivity than 252 
BEAMing.  FoundationACT
®
 is a hybrid-capture-based assay that is designed to interrogate 253 
62 genes, identifying all classes of alterations including base substitutions, insertions and 254 
deletions, copy number variations, and rearrangements/fusions through computational 255 
algorithms (20). 256 
Statistical analysis 257 
In each study, it was estimated that approximately 350 patients were needed to be tested via 258 
BEAMing to identify 15 patients with mutated RAS in stage 1, and that approximately 259 
2300 patients would need to be tested via BEAMing to identify a sufficient number of 260 
patients with mutated RAS to be treated in stage 2. 261 
Descriptive statistics were calculated for the presented endpoints. 262 
Results 263 
Patient disposition, demographics, and baseline characteristics 264 
In the refametinib monotherapy study, 498 patients were enrolled at 58 study centers in 265 
17 countries across Asia, Europe, and the USA from September 2013 to June 2014.  RAS 266 
mutational testing was performed in 493 patients (Fig. 1A); 32 (6.5%) had a RAS mutation.  267 
In the refametinib plus sorafenib study, 820 patients were enrolled at 80 study centers in 268 
21 countries across Asia, Europe, and the USA from September 2013 to April 2015.  RAS 269 
mutational testing was performed in 815 patients (Fig. 1B); 27 (3.3%) had a RAS mutation.  270 
Overall, 4.4% of HCC patients screened (59/1318) had a RAS mutation determined by 271 
BEAMing.  Of those, 32/59 patients received treatment, either refametinib monotherapy 272 
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(n = 16) or refametinib plus sorafenib (n = 16).  Reasons for patients not receiving treatment 273 
are summarized in Fig. 1. 274 
In the refametinib monotherapy study, the median age was 69 years and the median time 275 
since initial HCC diagnosis was 72.1 weeks (Table 1).  Nine patients (56.3%) had received 276 
prior first-line sorafenib treatment.  In the refametinib plus sorafenib study, the median age 277 
was 67 years and the median time since initial HCC diagnosis was 32.2 weeks (Table 1).  278 
Demographics and baseline characteristics were similar between patients irrespective of RAS 279 
mutational status in both studies. 280 
Efficacy 281 
Of the 16 patients treated with refametinib monotherapy, no patient had a CR or PR when 282 
centrally assessed according to mRECIST, and the ORR was 0% (Table 2).  One patient 283 
(6.3%) achieved an unconfirmed PR and eight (50.0%) achieved stable disease; the disease 284 
control rate was 56.3%.  ORR was 0% by independent assessment according to RECIST 285 
version 1.1: no patients had a CR or PR, 10 (62.5%) had stable disease, two (12.5%) had 286 
disease progression, and four (25.0%) were not evaluable.  The investigator-assessed ORR 287 
was 0% according to mRECIST (Supplementary Table S1) and RECIST version 1.1: 288 
no patients had a confirmed or unconfirmed CR or PR, 10 (62.5%) had stable disease, 289 
two (12.5%) had disease progression, and four (25.0%) were not evaluable. 290 
Of the 16 patients treated with refametinib plus sorafenib, one patient (6.3%) achieved a 291 
confirmed PR when centrally assessed according to mRECIST, and the ORR was 6.3% 292 
(Table 2).  Two patients (12.5%) achieved unconfirmed PRs (confirmatory computed 293 
tomography scan showed progression) and four (25.0%) had stable disease; the disease 294 
control rate was 43.8%.  Independent assessment according to RECIST version 1.1 reported 295 
an ORR of 6.3%: one patient (6.3%) had a confirmed PR, six (37.5%) had stable disease, 296 
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five (31.3%) had disease progression, and four (25.0%) were not evaluable or had data 297 
missing.  Investigator-assessed ORR was 6.3% according to mRECIST (one patient [6.3%] 298 
had a confirmed PR) (Supplementary Table S1).  The investigator-assessed ORR was also 299 
6.3% according to RECIST version 1.1: one patient (6.3%) had a PR, one (6.3%) had an 300 
unconfirmed PR, five (31.3%) had stable disease, six (37.5%) had disease progression, and 301 
three (18.8%) had missing data. 302 
In the refametinib monotherapy study, four patients (25.0%) had radiologic progression and 303 
the median time to progression was 2.8 months (Fig. 2A).  Seven patients (43.8%) in the 304 
refametinib plus sorafenib study had radiologic progression and the median time to 305 
progression was 2.8 months (Fig. 2B). 306 
Duration of response could not be calculated in the refametinib monotherapy study because 307 
no patient achieved a CR or PR.  Duration of response based on central assessment in the 308 
refametinib plus sorafenib study was 1.4 months for the one patient who achieved a 309 
confirmed PR; this patient had a KRAS
G35A
 point mutation.  Duration of response was 310 
2.7 months for the one patient who was investigator-assessed as achieving a confirmed PR; 311 
this patient had a KRAS
G38A
 mutation. 312 
In the refametinib monotherapy study, nine patients (56.3%) had disease progression or died 313 
and median progression-free survival was 1.9 months (Fig. 2C).  Eight patients (50.0%) died 314 
and median overall survival was 5.8 months (Fig. 2E).  In the refametinib plus sorafenib 315 
study, 10 patients (62.5%) had disease progression or died and median progression-free 316 
survival was 1.5 months (Fig. 2D).  Nine patients (56.3%) died and median overall survival 317 
was 12.7 months (Fig. 2F). 318 
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Exposure and dose modifications 319 
With refametinib monotherapy, the median duration of treatment (including interruptions) 320 
was 7.14 weeks.  The mean (± standard deviation) daily dose of refametinib (excluding 321 
interruptions) was 90.01 ± 13.88 mg. 322 
With refametinib plus sorafenib, the median durations of treatment (including interruptions) 323 
for refametinib and sorafenib were 8.21 weeks and 6.43 weeks, respectively.  The mean 324 
(± standard deviation) daily doses (excluding interruptions) of refametinib and sorafenib were 325 
85.06 ± 16.07 mg and 514.24 ± 124.23 mg, respectively.  The majority of patients 326 
experienced treatment-emergent AEs (TEAEs) of hand-foot skin reaction, fatigue, or 327 
gastrointestinal toxicities of grade ≥2 in cycle 1, so only three patients (18.8%) received the 328 
full dose of sorafenib (800 mg/day) following cycle 1.  One patient remained on treatment at 329 
the time of data-cut off and has been ongoing for approximately 2 years. 330 
TEAEs led to dose modification (interruption or reduction) in 14 patients (87.5%) receiving 331 
refametinib monotherapy (Table 3) and were considered drug-related in 13 patients (81.3%).  332 
Treatment was permanently discontinued because of TEAEs in four patients (25.0%) and 333 
were considered drug-related in three patients (18.8%). 334 
With refametinib plus sorafenib, dose modifications were reported in 11 patients (68.8%) 335 
with refametinib and 11 patients (68.8%) with sorafenib.  TEAEs led to dose modification in 336 
15 patients (93.8%) (Table 3); events were considered refametinib-related in 13 patients 337 
(81.3%) and sorafenib-related in 14 patients (87.5%). 338 
Safety 339 
At least one TEAE was reported in all 16 patients (100%) receiving refametinib monotherapy 340 
(Table 3).  The most common TEAEs of worst grade 3 were fatigue and increased CPK 341 
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(three patients each [18.8%]).  Grade 5 TEAEs occurred in five patients (31.3%): sepsis, 342 
death not otherwise specified, multi-organ failure, lung infection, and heart failure.  The 343 
causes of death were progressive disease (one patient) and AE associated with clinical 344 
disease progression and AE not associated with clinical disease progression (two patients 345 
each).  Drug-related TEAEs occurred in 14 patients (87.5%) (Supplementary Table S2).  In 346 
most patients (75.0%), the worst grade of drug-related TEAEs was grade 3, and one patient 347 
(6.3%) had a drug-related TEAE of grade 4 (increased serum amylase).  Twelve patients 348 
(75.0%) experienced SAEs (Supplementary Table S3), of which the most common worst 349 
grade was grade 3 (43.8%).  SAEs were refametinib-related in seven patients (43.8%), most 350 
commonly increased CPK (three patients [18.8%]).  All other refametinib-related SAEs were 351 
reported in one patient each (6.3%) (Supplementary Table S3). 352 
TEAEs occurred in all 16 patients (100%) receiving refametinib plus sorafenib (Table 3).  353 
Hand-foot skin reaction was reported in two patients (12.5%).  The most common TEAEs of 354 
worst grade 3 were hypertension (10/16 [62.5%]) and increased aspartate aminotransferase 355 
and increased CPK in five patients each (31.3%).  Seven TEAEs of worst grade 4 were 356 
reported in three patients (18.8%): increased aspartate aminotransferase, increased CPK, 357 
decreased platelet count, investigations - other, hypophosphatemia, and hyperuricemia.  358 
Grade 5 TEAEs included general disorders and administration site conditions - other and 359 
dyspnea (one patient each); the cause of death was AE associated with clinical disease 360 
progression and progressive disease (one patient each).  Refametinib- and sorafenib-related 361 
TEAEs were reported for all 16 patients (100%) (Supplementary Table S2).  Nine patients 362 
(56.3%) had refametinib-related TEAEs of grade 3 and three patients (18.8%) had 363 
refametinib-related TEAEs of grade 4 (Supplementary Table S2).  Twelve patients (75.0%) 364 
had sorafenib-related TEAEs of worst grade 3 and three patients (18.8%) had sorafenib-365 
related TEAEs of worst grade 4.  One patient (6.3%) had a grade 5 TEAE considered related 366 
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to both refametinib and sorafenib (general disorders and administration site conditions - 367 
other).  SAEs were reported in 13 patients (81.3%) (Supplementary Table S3), most 368 
commonly increased CPK in six patients (37.5%; five grade 3, one grade 4).  Refametinib-369 
related SAEs were experienced by 12 patients (75.0%), most frequently worst grade 3 (7/16 370 
[43.8%]).  Increased CPK was the most commonly reported refametinib-related SAE (5/16 371 
[31.3%]; four grade 3, one grade 4).  Sorafenib-related SAEs occurred in 10 patients (62.5%); 372 
seven patients (43.8%) had events of worst grade 3 and one patient (6.3%) experienced worst 373 
grade 4 (increased CPK).  One SAE of grade 5 was considered refametinib-related and 374 
sorafenib-related (general disorders and administration site conditions - other). 375 
Biomarker analyses 376 
To identify potential genomic biomarkers which might be associated with resistance to 377 
refametinib monotherapy or combination therapy, NGS (FoundationACT
®
) was performed 378 
on available ctDNA from 27 patients (refametinib monotherapy, n = 15; refametinib plus 379 
sorafenib, n = 12).  RAS mutations were not called by NGS in over 60% of the samples with a 380 
mutant allele frequency of between 0.02% and 0.1% as determined by BEAMing.  RAS 381 
mutational status was confirmed by NGS in 12 patients (44.4%), all with a mutant allele 382 
frequency above 0.1%.  The RAS somatic aberration detected was concordant with BEAMing 383 
results in 11 patients (91.7%).  Excluding RAS, the most frequently detected mutation was in 384 
the promoter region of telomerase reverse transcriptase (TERT; 17/27 [63.0%]), followed by 385 
TP53 (13/27 [48.1%]), and β-catenin (CTNNB1; 10/27 [37.0%]) (Fig. 3).  Actionable 386 
mutations were rare (<10%) and included oncogenes such as EGFR, JAK2, BRAF, FLT3, 387 
PIK3CA, and cKIT. 388 
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Discussion 389 
These two phase II proof-of-concept studies prospectively evaluated the efficacy and safety 390 
of refametinib monotherapy or refametinib plus sorafenib in patients prospectively screened 391 
for RAS-mutant unresectable or metastatic HCC based on evaluation of mutational status in 392 
ctDNA.  The previous phase II BASIL trial in a separate population of Asian patients with 393 
HCC receiving refametinib plus sorafenib demonstrated that the majority of patients who 394 
responded to this regimen had mutant RAS tumors, with an ORR of 75% in patients with 395 
RAS-mutant HCC compared with 1.5% in HCC patients with no RAS mutation (17). 396 
In these studies, prospective testing for RAS mutations using ctDNA isolated from plasma 397 
was a feasible, non-invasive approach for large-scale mutational testing in HCC patients.  398 
The current findings support a previous report of the use of ctDNA to detect KRAS mutations 399 
via BEAMing in a small study of patients with refractory colorectal carcinoma treated with 400 
regorafenib (21), although KRAS mutational frequency was notably higher in the colorectal 401 
carcinoma population (~40%) compared with that reported here (~5%).  Overall, 59/1318 402 
(4.4%) of the HCC patients screened had a RAS mutation.  The RAS mutation rates reported 403 
here are consistent with previous reports in this patient population (~5%) (22-25).  It should 404 
therefore be noted that the low RAS mutational frequency in this population suggests that 405 
identifying RAS-mutant patients may be challenging in practice. 406 
The primary efficacy variable was not met in the refametinib monotherapy study, with no 407 
patient with mutated RAS achieving a CR or PR.  In the refametinib plus sorafenib study, one 408 
patient with mutated RAS achieved a PR, resulting in an ORR of 6.3%, which is broadly 409 
similar to the ORR of 6.9% reported in the BASIL trial (17). 410 
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The target for the first stage of the trials (≥5/15 patients with a CR or PR) was not reached; 411 
therefore, these studies did not proceed to the planned evaluation of refametinib monotherapy 412 
or combination therapy in a larger number of patients.  Further exploration would be required 413 
to understand the lower ORR with refametinib plus sorafenib in this study compared with 414 
previous reports (17).  These results suggest that the use of RAS mutational status as a 415 
prognostic biomarker for treatment response to refametinib monotherapy or in combination 416 
with sorafenib was unsuccessful, and targeting MEK with refametinib in this RAS-mutant 417 
patient population did not lead to a significant proportion of objective responses.  However, 418 
the low number of patients treated should be taken into account, and the low proportion of 419 
responses observed may reflect random error – these results should therefore be interpreted 420 
with caution.  Additional molecular events may explain the limited responses seen using 421 
mutated RAS as a prognostic biomarker for targeted MEK inhibition in these studies.  It is 422 
possible that with intra-tumor heterogeneity, mutations occurring in low-frequency subclonal 423 
tumor cell populations may have acquired mutations that conferred resistance to refametinib, 424 
which was targeted to progenitor cells expressing truncal driver mutations in RAS, negatively 425 
affecting clinical outcomes (26).  Evaluation of non-truncal mutations, together with longer-426 
term evaluations of changes in allele frequency, were not planned in this study, although may 427 
provide useful insights into the development of resistance to refametinib in patients with 428 
HCC. 429 
Median overall survival was 5.8 months with refametinib monotherapy and 12.7 months with 430 
refametinib plus sorafenib, with over half of events occurring during the study period.  KRAS 431 
mutation is generally associated with poorer outcomes in most cancers, although there are no 432 
established data in HCC due to the lack of robust testing in large studies of advanced disease 433 
(23).  In our study, the effect of refametinib monotherapy on overall survival can be 434 
considered insignificant, since the expected outcome of placebo at first or second line is 7–8 435 
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months (27,28).  In fact, this survival of under 6 months might indicate that advanced RAS-436 
positive HCC tumors have a poor natural history.  It should also be noted that 56% of patients 437 
in the monotherapy arm had received prior sorafenib, possibly contributing to the poor 438 
survival seen.  However, the approximately 13-month survival outcome with refametinib plus 439 
sorafenib treatment is more intriguing, considering the expected median survival with first-440 
line sorafenib monotherapy alone is 11 months (29).  This result may indicate a synergistic 441 
effect between sorafenib and refametinib, which is relevant as tumors harboring RAS 442 
mutations remain some of the most challenging to treat because of the paucity of successful 443 
drugs targeting the RAS pathway (30).  However, this finding should be interpreted with 444 
caution because of the heterogeneity in baseline liver function and tumor factors, which could 445 
affect response to treatment.  Also, patients in the refametinib plus sorafenib study had a 446 
much shorter median time from initial diagnosis to study treatment compared with patients in 447 
the monotherapy study (32.1 weeks vs. 72.1 weeks, respectively).  The overall survival 448 
findings in the combination study support those described for patients receiving refametinib 449 
plus sorafenib in the BASIL trial (17), although median overall survival was increased in our 450 
study (12.7 months vs. 9.5 months, respectively). 451 
Median time to progression was the same across the refametinib monotherapy and 452 
refametinib plus sorafenib studies (2.8 months), with similar median progression-free 453 
survival observed between the studies (1.9 months and 1.5 months, respectively).  However, 454 
progression-free survival times were lower than previous reports (17). 455 
Drug exposure was similar between both studies and similar to the median refametinib dose 456 
observed in the BASIL study (17).  The majority of patients in the refametinib plus sorafenib 457 
study experienced AEs during cycle 1 that prevented sorafenib dose escalation to 800 mg per 458 
day, which was also observed in the BASIL study (17).  The majority of patients across both 459 
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studies experienced AEs leading to dose modifications, which may have caused insufficient 460 
drug exposure, potentially leading to reduced efficacy of both refametinib regimens.  Overall, 461 
median duration of treatment was relatively short in both trials (7 weeks and 8 weeks, 462 
respectively), similar to that reported for the BASIL study (8 weeks) (17). 463 
Overall, refametinib was tolerated as monotherapy and combination therapy, and the majority 464 
of TEAEs were manageable in both studies.  In patients receiving refametinib monotherapy, 465 
the most common TEAEs of limb edema, fatigue, nausea, and vomiting were consistent with 466 
the safety profile previously reported in a phase I study of refametinib (31).  The high overall 467 
incidence of grade 3 TEAEs irrespective of causality in both studies (68.8%) was similar to 468 
that reported in the BASIL trial (60.0%) (17).  Generally, the observed incidence and severity 469 
of refametinib-related TEAEs observed with refametinib monotherapy were comparable with 470 
data from the previous refametinib phase I study (31).  Refametinib-related SAEs were less 471 
frequent with refametinib monotherapy than with refametinib plus sorafenib (43.8% vs. 472 
75.0%, respectively).  Increased CPK grade ≥3 was the most common refametinib-related 473 
SAE reported in both studies, consistent with reports of increased CPK as a class effect of 474 
MEK inhibitors (32-34). 475 
Compared with the known safety profile of sorafenib monotherapy (29,35), a higher 476 
incidence of liver and gastrointestinal toxicities and rash was observed in patients who 477 
received refametinib plus sorafenib.  However, alopecia and hand-foot skin reaction were less 478 
common compared with those reported for sorafenib monotherapy (14% vs. 12.5% and 21% 479 
vs. 6.3%, respectively) (29), possibly due to the reduced exposure to sorafenib in the majority 480 
of patients in our study. 481 
Biomarker analysis of ctDNA analyzed by NGS showed the observed mutational landscape 482 
to be consistent with published data for HCC (36).  The most common mutation was in the 483 
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promoter region of TERT, supporting previous observations in patients with HCC and 484 
combined HCC-cholangiocarcinoma (37,38).  Few actionable mutations were found, with 485 
none appearing to explain the resistance to refametinib alone or in combination with 486 
sorafenib, and few of the detected mutations are feasible for targeting with existing drugs.  It 487 
therefore remains inconclusive from our results as to whether somatic mutations in oncogenes 488 
affect the efficacy of refametinib in monotherapy or combination therapy.  Although analyses 489 
were planned to evaluate the role of biomarkers in the response to treatment, due to limited 490 
sample size and early study termination it was not possible to fully address the role of intra-491 
tumor heterogeneity (26).  In addition, although the two study populations included only 492 
Child-Pugh A patients, these patients were heterogeneous for various factors that may be 493 
prognostic for treatment response, such as a history of ascites (in four patients overall 494 
[12.5%]) (39), alpha-fetoprotein (>400 µg/L in 12 patients [37.5%]) (40), microvascular 495 
invasion (in 11 patients [34%]) (41), extrahepatic spread (in 16 patients [50%]) (41), and 496 
hepatitis C (in seven patients [21.9%]) (41).  However, no formal analysis of lung function 497 
status and tumor factors as prognostic markers for treatment response was planned in these 498 
studies. 499 
In these studies, RAS mutational status as determined by BEAMing was confirmed in 44% of 500 
samples using NGS, all with mutant allele frequencies of 0.1% or higher.  Although 501 
BEAMing technology is highly sensitive (42), the newly developed NGS from ctDNA 502 
approach has demonstrated high concordance, confirming nearly all mutations identified by 503 
BEAMing, and offers the additional advantage of providing the mutational landscape based 504 
on ctDNA.  A comparison of sensitivity between both assays is difficult due to the different 505 
detection limit of each method (0.02% for BEAMing vs. 0.1% for NGS), which did not allow 506 
for the detection of RAS mutational status by NGS in over 60% of samples with mutant allele 507 
frequency between 0.02% and 0.1%.  Nonetheless, our results demonstrated that NGS 508 
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appears to be a promising non-invasive approach to determine the landscape of somatic 509 
mutations, particularly for patients in whom a biopsy is not an option (19). 510 
Despite the poor ORR in patients with RAS mutations, a median overall survival of 511 
13 months in the small population included in the refametinib plus sorafenib study may 512 
indicate a synergistic effect between refametinib and sorafenib that should be further 513 
explored in a larger patient population that is not stratified by RAS mutational status, taking 514 
into account other prognostic factors based on patient heterogeneity and intra-tumor 515 
heterogeneity.  The analysis of mutational status using ctDNA isolated from plasma as a 516 
liquid biopsy was a feasible, non-invasive technique in patients with unresectable or 517 
metastatic HCC, although RAS mutational frequency was low.  Further analysis of this 518 
technique is warranted for discovery of predictive biomarkers in HCC and other cancers.  519 
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Table 1.  Demographics and baseline characteristics of patients receiving refametinib 
monotherapy or refametinib plus sorafenib 
 Refametinib 
monotherapy  
(n = 16) 
Refametinib 
plus sorafenib  
(n = 16) 
Male, n (%) 13 (81.3) 12 (75.0) 
Race, n (%)   
White 9 (56.3) 9 (56.3) 
Asian 7 (43.8) 6 (37.5) 
Black or African American 0 1 (6.3) 
Median age, years (range) 69 (37–84) 67 (53–82) 
Median body mass index, kg/m
2
 (range) 23.7 (20.5–31.8) 23.6 (16.4–34.8) 
Baseline ECOG PS, n (%)   
0 7 (43.8) 10 (62.5) 
1 9 (56.3) 6 (37.5) 
Medical history, n (%)
a
   
Hepatic cirrhosis 14 (87.5) 11 (68.8) 
Ascites 3 (18.8) 1 (6.3) 
Gastroesophageal reflux disease 3 (18.8) 1 (6.3) 
Abdominal pain
b
 2 (12.5) 2 (12.5) 
Esophageal varices 2 (12.5) 1 (6.3) 
Portal hypertension 1 (6.3) 2 (12.5) 
Confirmation of liver cirrhosis, n (%)   
Histologic 4 (25.0) 3 (18.8) 
Clinical 10 (62.5) 5 (31.3) 
Histologic and clinical 0 3 (18.8) 
Missing 2 (12.5) 5 (31.3) 
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Etiology of HCC, n (%)   
Alcohol use 6 (37.5) 3 (18.8) 
Alcohol use/genetic/metabolic 0 1 (6.3) 
Alcohol use/hepatitis B 2 (12.5) 0 
Alcohol use/hepatitis C 0 1 (6.3) 
Hepatitis B 2 (12.5) 5 (31.3) 
Hepatitis C 3 (18.8) 4 (25.0) 
Non-alcoholic steatohepatitis 1 (6.3) 1 (6.3) 
Unknown 2 (12.5) 1 (6.3) 
Overall Child-Pugh A score, n (%)   
5 8 (50.0) 10 (62.5) 
6 8 (50.0) 6 (37.5) 
BCLC stage, n (%)   
A (early) 0 2 (12.5) 
B (intermediate) 2 (12.5) 2 (12.5) 
C (advanced) 14 (87.5) 12 (75.0) 
Presence of macrovascular invasion, n (%) 4 (25.0) 7 (43.8) 
Presence of extrahepatic spread, n (%) 10 (62.5) 6 (37.5) 
Alpha-fetoprotein >400 µg/L, n (%) 9 (56.3)
c
 3 (18.8) 
Bilirubin, mg/dL, median (range) 0.9 (0.4–2.3) 0.7 (0.3–1110.9) 
Albumin, g/dL, median (range) 3.9 (2.8–4.3) 3.9 (3.2–38.0) 
Prothrombin INR, median (range) 1.1 (0.9–1.3) 1.1 (0.9–1.2) 
Median time since initial diagnosis, weeks 
(range) 
72.1 (5.9–262.3) 32.2 (8.1–342.7) 
Median time since most recent progression, 
weeks (range) 
8.6 (1.1–57.0) 8.6 (3.1–21.0) 
Prior anticancer therapies and procedures, n (%)   
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a
In two or more patients overall; 
b
Includes upper and lower abdominal pain in one patient 
each in the combination study; 
c
Baseline data missing for one patient. 
Abbreviation: BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative 
Oncology Group performance status; INR, international normalized ratio. 
  
Surgical therapeutic procedure 6 (37.5) 9 (56.3) 
Systemic anticancer therapy (sorafenib) 9 (56.3) 0 
Local anticancer therapy 6 (37.5) 8 (50.0) 
Number of target lesions (mRECIST), n (%)   
1 2 (12.5) 4 (25.0) 
2 10 (62.5) 10 (62.5) 
3 4 (25.0) 1 (6.3) 
4 0 1 (6.3) 
Number of non-target lesions (mRECIST), n (%)   
0 4 (25.0) 6 (37.5) 
1 9 (56.3) 8 (50.0) 
2 2 (12.5) 0 
3 1 (6.3) 1 (6.3) 
4 0 1 (6.3) 
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Table 2.  Response evaluation by central assessment using mRECIST in patients receiving 
refametinib monotherapy or refametinib plus sorafenib 
n (%) [95% CI] Refametinib 
monotherapy  
(n = 16) 
Refametinib 
plus sorafenib  
(n = 16) 
Best overall response   
Complete response 0 0 
Confirmed partial response 0 1 (6.3) [0.16–30.23] 
Unconfirmed partial response 1 (6.3) [0.16–30.23] 2 (12.5) [7.27–52.38] 
Stable disease 8 (50.0) [24.65–75.35] 4 (25.0) [7.27–52.38] 
Disease progression 3 (18.8) [4.05–45.65] 5 (31.3) [11.02–58.66] 
Not evaluable 0 1 (6.3) [0.16–30.23] 
Missing 4 (25.0) [7.27–52.38] 3 (18.8) [4.05–45.65] 
Objective tumor response rate 0 1 (6.3) [0.16–30.23] 
Disease control rate
a
 9 (56.3) [29.88–80.25] 7 (43.8) [19.75–70.12] 
a
Includes unconfirmed complete and partial responses ≥6 weeks from baseline assessment. 
Abbreviation: CI, confidence interval. 
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Table 3.  Summary of safety and incidence of treatment-emergent adverse events (by worst 
CTCAE grade) occurring in three or more patients receiving refametinib monotherapy or 
refametinib plus sorafenib 
n (%) Refametinib 
monotherapy  
(n = 16) 
Refametinib 
plus sorafenib  
(n = 16) 
Any TEAE
a 
16 (100) 16 (100) 
Worst grade   
3 11 (68.8) 11 (68.8) 
4 0 3 (18.8) 
5 (death) 5 (31.3) 2 (12.5) 
Serious adverse events 12 (75.0) 13 (81.3) 
Led to dose modification 14 (87.5) 15 (93.8) 
Led to permanent discontinuation 4 (25.0) 5 (31.3) 
Incidence of TEAEs (any grade) 
occurring in ≥10% of the total population 
  
Limb edema 7 (43.8) 3 (18.8) 
Fatigue 6 (37.5) 12 (75.0) 
Nausea 6 (37.5) 2 (12.5) 
Vomiting 6 (37.5) 5 (31.3) 
Increased creatine phosphokinase 5 (31.3) 8 (50.0) 
Diarrhea 5 (31.3) 10 (62.5) 
Acneiform rash 5 (31.3) 8 (50.0) 
Increased aspartate aminotransferase 4 (25.0) 8 (50.0) 
Maculo-papular rash 4 (25.0) 6 (37.5) 
Hypertension 4 (25.0) 13 (81.3) 
Anemia 3 (18.8) 2 (12.5) 
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Abdominal pain 3 (18.8) 2 (12.5) 
Ascites 3 (18.8) 3 (18.8) 
Anorexia 3 (18.8) 4 (25.0) 
Hypoglycemia 3 (18.8) 0 
Back pain 3 (18.8) 1 (6.3) 
Dyspnea 3 (18.8) 2 (12.5) 
Dry skin 3 (18.8) 2 (12.5) 
Skin and subcutaneous tissue 
disorders - other, specify 
3 (18.8) 0 
Oral mucositis 2 (12.5) 5 (31.3) 
Hypoalbuminemia 2 (12.5) 4 (25.0) 
Decreased platelet count 2 (12.5) 4 (25.0) 
Constipation 2 (12.5) 3 (18.8) 
Investigations - other, specify 2 (12.5) 3 (18.8) 
Hyperglycemia 2 (12.5) 3 (18.8) 
Increased alanine aminotransferase 1 (6.3) 3 (18.8) 
Malaise 1 (6.3) 3 (18.8) 
Skin infection 1 (6.3) 3 (18.8) 
Headache 0 3 (18.8) 
Increased lipase 0 3 (18.8) 
a
Number (%) of patients with the specified event starting or worsening between the start of 
treatment and 30 days after the end of treatment. 
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events. 
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Figure legends 
Figure 1.  Patient disposition in the two phase II studies.  (A) Refametinib monotherapy 
study.  (B) Refametinib plus sorafenib study. 
Figure 2.  Kaplan-Meier curves of TTP, PFS, and OS in the two phase II studies.  (A) TTP in 
patients who received refametinib monotherapy.  (B) TTP in patients who received 
refametinib plus sorafenib.  (C) PFS in patients who received refametinib monotherapy.  
(D) PFS in patients who received refametinib plus sorafenib.  (E) OS in patients who received 
refametinib monotherapy.  (F) OS in patients who received refametinib plus sorafenib.  
Abbreviations: CI, confidence interval; NE, not estimable due to censored data; OS, overall 
survival; PFS, progression-free survival; TTP, time to progression. 
Figure 3.  Somatic aberrations of patients with RAS mutations as detected in circulating 
tumor DNA.  Abbreviations: r, rearrangement; s, short variant. 
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